ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Código da empresaNDRA
Nome da EmpresaENDRA Life Sciences Inc
Data de listagemJun 28, 2017
Fundado em2007
CEOMr. Alexander Y. Tokman
Funcionários21
Tipo de TítulosOrdinary Share
Fim do ano fiscalJun 28
Endereço3600 Green Ct Ste 350
CidadeANN ARBOR
Bolsa de ValoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal48105-2440
Telefone17343350468
Sitehttps://www.endrainc.com/
Código da empresaNDRA
Data de listagemJun 28, 2017
Fundado em2007
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados